It exhibits efficacy in crizotinib-naive and crizotinib-resistant patients with ALK-positive, locally advanced or metastatic NSCLC, as well as patients with brain metastases.34 A phase III study is ongoing to compare ensartinib with crizotinib for the first-line treatment of ALK-positive NSCLC (NCT02767804). Here, ALK is linked to non-small cell lung carcinoma.